EpilepsyGTx Raises $10M for Lead Gene Therapy Program

EpilepsyGTx raises $10M in Seed Funding

EpilepsyGTx (Linkedin), a biotech company based in the United States, has secured $10M in seed funding to advance their gene therapies for focal refractory epilepsy. With plans for a first-in-human clinical study, EpilepsyGTx aims to provide hope and relief for individuals suffering from this treatment-resistant form of epilepsy.

Funding Amount: $10 million

Industry: E-Learning Providers

Employee Count: 2-10

CEO: Lindsay Tjepkema (CEO Linkedin)

What EpilepsyGTx needs to buy: EpilepsyGTx is seeking partnerships with research organizations, clinical trial sites, and regulatory consultants to support their gene therapy programs. Companies specializing in gene therapy research, clinical trial services, and regulatory compliance can play a crucial role in helping EpilepsyGTx bring their innovative treatments to patients in need.